Stevens Timothy P, Sinkin Robert A
Golisano Children's Hospital at Strong, University of Rochester, Rochester, NY, USA.
Chest. 2007 May;131(5):1577-82. doi: 10.1378/chest.06-2371.
Surfactant replacement therapy (SRT) has a proven role in the treatment of neonatal respiratory distress syndrome and severe meconium aspiration syndrome in infants, and may have a role in the treatment of pediatric patients with ARDS. Although newer delivery mechanisms and strategies are being studied, the classic surfactant administration paradigm consists of endotracheal intubation, surfactant instillation into the lung, and stabilization with mechanical ventilation followed by extubation when stable on low respiratory support. Currently, this surfactant administration procedure is bundled into Current Procedural Terminology (CPT) codes used when providing intensive care. A specific CPT code for surfactant administration is scheduled to be introduced in 2007. This article reviews clinical issues in SRT and the practice management considerations necessary to provide this care.
表面活性剂替代疗法(SRT)在治疗新生儿呼吸窘迫综合征和婴儿严重胎粪吸入综合征方面已被证实具有作用,并且可能在治疗小儿急性呼吸窘迫综合征(ARDS)患者中发挥作用。尽管正在研究更新的给药机制和策略,但经典的表面活性剂给药模式包括气管插管、将表面活性剂滴入肺内、用机械通气进行稳定,然后在低呼吸支持下稳定时拔管。目前,这种表面活性剂给药程序被纳入提供重症监护时使用的现行程序编码(CPT)中。专门用于表面活性剂给药的CPT编码计划于2007年推出。本文回顾了表面活性剂替代疗法中的临床问题以及提供这种治疗所需的实践管理考虑因素。